

CITATION REPORT

List of articles citing

Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms

DOI: 10.1016/j.pharmthera.2018.04.009

Pharmacology & Therapeutics, 2018, 189, 89-103.

Source: <https://exaly.com/paper-pdf/69316579/citation-report.pdf>

Version: 2024-04-11

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
81	Lactobacillus supplementation prevents cisplatin-induced cardiotoxicity possibly by inflammation inhibition. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 999-1008	3.5	19
80	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies - part 1. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 875-892	4.1	12
79	Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. <i>Circulation</i> , 2019 , 140, 1070-1080	16.7	49
78	Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2019 , 112, 699-712	2.7	12
77	Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement From the American Heart Association. <i>Circulation Research</i> , 2019 , 125, e75-e92	15.7	55
76	Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic Implications. <i>BioDrugs</i> , 2019 , 33, 613-628	7.8	8
75	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1667-1678	15.1	85
74	Cardiac arrhythmia considerations of hormone cancer therapies. <i>Cardiovascular Research</i> , 2019 , 115, 878-894	9.9	33
73	Role of oxidative stress in cardiotoxicity of antineoplastic drugs. <i>Life Sciences</i> , 2019 , 232, 116526	6.8	4
72	Chemotherapy-Related Cardiovascular Complications. 2019 , 1-23		2
71	Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. <i>Cardiovascular Research</i> , 2019 , 115, 922-934	9.9	32
70	Bruton Tyrosine Kinase Inhibitors: Present and Future. <i>Cancer Journal (Sudbury, Mass.)</i> , 2019 , 25, 386-393	3.2	34
69	Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. <i>Life Sciences</i> , 2019 , 218, 112-131	6.8	80
68	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2020 , 113, 9-21	2.7	15
67	Hypertension and QT interval prolongation associated with targeted systemic cancer therapies. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1987-1996	1.7	
66	The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia. <i>Current Heart Failure Reports</i> , 2020 , 17, 365-383	2.8	13
65	Cardiac Disease in Childhood Cancer Survivors: Risk Prediction, Prevention, and Surveillance: State-of-the-Art Review. <i>JACC: CardioOncology</i> , 2020 , 2, 363-378	3.8	11

64	The Hidden Fragility in the Heart of the Athletes: A Review of Genetic Biomarkers. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	7
63	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. <i>Journal of the American Heart Association</i> , 2020 , 9, e018403	6	44
62	Electrocardiographic characteristics of diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy. <i>Journal of Electrocardiology</i> , 2020 , 60, 195-199	1.4	4
61	The role of metabolic diseases in cardiotoxicity associated with cancer therapy: What we know, what we would know. <i>Life Sciences</i> , 2020 , 255, 117843	6.8	2
60	Cytochrome P450 Inhibition. 2020 , 183-261		
59	Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 321-323	6.4	1
58	The current role of BTK inhibitors in the treatment of Waldenström's Macroglobulinemia. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 663-674	3.5	4
57	Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes". <i>Circulation</i> , 2020 , 141, e63-e64	16.7	
56	Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 312-320	6.4	17
55	Five-year follow-up observation of interventional therapy for lower extremity vascular disease in type 2 diabetes and analysis of risk factors for restenosis. <i>Journal of Diabetes</i> , 2021 , 13, 134-142	3.8	2
54	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <i>Therapeutic Advances in Hematology</i> , 2021 , 12, 2040620721989586	5.7	4
53	CHAPTER 19:Cardiac Ion Channel Inhibition. <i>RSC Drug Discovery Series</i> , 2021 , 403-492	0.6	
52	The Beneficial Effects of Saffron Extract on Potential Oxidative Stress in Cardiovascular Diseases. <i>Oxidative Medicine and Cellular Longevity</i> , 2021 , 2021, 6699821	6.7	7
51	Atrial Cardiomyopathy and Atrial Fibrillation in Cancer. <i>Cardiology Research and Practice</i> , 2021 , 2021, 6685953	1.9	0
50	Sexual Dimorphisms, Anti-Hormonal Therapy and Cardiac Arrhythmias. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
49	Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021 , 197, 113968	3.5	4
48	Kanker als hartenbreker: cardio-oncologie, meer dan alleen hartfalen?. <i>Tijdschrift Voor Geneeskunde</i> , ,	1	
47	Efficient Synthesis and Bioevaluation of Novel Dual Tubulin/Histone Deacetylase 3 Inhibitors as Potential Anticancer Agents. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 8447-8473	8.3	8

46	Risk of Atrial Fibrillation According to Cancer Type: A Nationwide Population-Based Study. <i>JACC: CardioOncology</i> , 2021 , 3, 221-232	3.8	4
45	Atrial Fibrillation and Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 590768	5.4	1
44	Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature. <i>Current Drug Safety</i> , 2021 ,	1.4	0
43	Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. <i>European Heart Journal</i> , 2021 , 42, 3915-3928	9.5	6
42	BrutonB tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation. <i>Current Oncology Reports</i> , 2021 , 23, 113	6.3	9
41	Key Characteristics of Cardiovascular Toxicants. <i>Environmental Health Perspectives</i> , 2021 , 129, 95001	8.4	7
40	Strategies to balance stroke and bleeding risk in patients with atrial fibrillation and cancer. <i>Heart Rhythm</i> , 2021 , 18, 1533-1538	6.7	
39	Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review. <i>Current Medicinal Chemistry</i> , 2020 , 27, 4673-4698	4.3	8
38	Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. <i>Russian Journal of Cardiology</i> , 2021 , 26, 4703	1.3	16
37	Comparative Therapeutic Potential of Cardioactive Glycosides in Doxorubicin Model of Heart Failure. <i>Cardiovascular Toxicology</i> , 2021 , 22, 78	3.4	
36	Chemotherapy-Related Cardiovascular Complications. 2020 , 815-836		
35	Drug Review: Ibrutinib. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020 , 41, 383-392	0.2	
34	Arrhythmia in tumor lysis syndrome and associated in-hospital mortality: A nationwide inpatient analysis. <i>Journal of Arrhythmia</i> , 2021 , 37, 121-127	1.5	1
33	An Overview of Pharmacological and Non-Pharmacological Treatment as a Useful Tool for the Protection from Cardiotoxicity of Antineoplastic Drugs. <i>Serbian Journal of Experimental and Clinical Research</i> , 2020 , 21, 263-270	0.3	
32	Abiraterone-induced refractory hypokalaemia and torsades de pointes in a patient with metastatic castration-resistant prostate carcinoma: a case report.. <i>European Heart Journal - Case Reports</i> , 2021 , 5, ytab462	0.9	1
31	Atrial Fibrillation in Cancer Patients: Who is at Risk?. <i>Rational Pharmacotherapy in Cardiology</i> , 2022 , 17, 900-907	0.5	2
30	Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity.. <i>Drug Safety</i> , 2022 , 45, 101	5.1	0
29	Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs.. <i>Frontiers in Oncology</i> , 2021 , 11, 814699	5.3	0

28 iPSCs and toxicology. **2022**, 529-569

27 Sonochemical fabrication of reduction-responsive alginate-based nanocapsules with folate targeting for drug delivery. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, **2022**, 639, 128349 5.1 2

26 Calcium dysregulation in heart diseases: Targeting calcium channels to achieve a correct calcium homeostasis.. *Pharmacological Research*, **2022**, 177, 106119 10.2 4

25 Hesperidin protects against cisplatin-induced cardiotoxicity in mice by regulating the p62-Keap1-Nrf2 pathway.. *Food and Function*, **2022**, 13, 4205-4215 6.1 0

24 Torsades de pointes in patients with cancer. **2022**, 285-301

23 Anticoagulation for atrial fibrillation in active cancer.. *Oncology Letters*, **2022**, 23, 124 2.6 0

22 Breast Cancer and Atrial Fibrillation.. *Journal of Clinical Medicine*, **2022**, 11, 5.1 0

21 Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association.. *Circulation*, **2022**, CIR0000000000001056 16.7 4

20 Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care.. *Children*, **2021**, 8, 2.8 0

19 Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 847012 5.4 0

18 Opportunities and Challenges in Cardio-Oncology:A Bibliometric analysis From 2010 to 2022.. *Current Problems in Cardiology*, **2022**, 101227 17.1 1

17 Cardiovascular risks of chemotherapy. **2023**, 20-35

16 Extended transit compartment model to describe tumor delay using Coxian distribution. *Scientific Reports*, **2022**, 12, 4.9

15 The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway. *Molecules*, **2022**, 27, 4452 4.8 1

14 Inhibition of cytochrome P450 2J2-mediated metabolism of rivaroxaban and arachidonic acid by ibrutinib and osimertinib. *Drug Metabolism and Disposition*, DMD-AR-2022-000928 4 1

13 Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. **2022**, 15, 1007 0

12 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). 4

11 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). 39

- 10 Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations. **2022**, 13, 204062072011165
- 9 Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Volume 16, 3225-3239 o
- 8 Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-OncologyPart 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias. 1
- 7 Proarrhythmic effects of cancer therapies. **2022**, 2, 16-22 o
- 6 In silico mechanisms of arsenic trioxide-induced cardiotoxicity. 13, o
- 5 Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study. **2023**, 7, 100026 o
- 4 Analysis of clinical characteristics and automatic monitoring of drug-induced arrhythmias in 167,546 inpatients. o
- 3 A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole. 10, o
- 2 Atrial fibrillation, cancer and anticancer drugs. **2023**, 116, 219-226 o
- 1 Atrial Fibrillation Incidence Associated With Exposure to Anticancer Drugs Used as Monotherapy in Clinical Trials. **2023**, 5, 216-226 o